Literature DB >> 3101600

Metabolism of NG,NG-and NG,N'G-dimethylarginine in rats.

T Ogawa, M Kimoto, H Watanabe, K Sasaoka.   

Abstract

The metabolic fates of NG,NG-and NG,N'G-dimethylarginines in rats were investigated isotopically and novel metabolites, alpha-keto-delta-(N,N-dimethylguanidino)-and alpha-keto-delta-(N,N'-dimethylguanidino)valeric acids and gamma-(N,N-dimethylguanidino)-and gamma-(N,N'-dimethylguanidino)butyric acids were identified. In the case of the rats injected with NG,NG-dimethyl-L-[1,2,3,4,5-14C]arginine, about 13% of the radioactivity was recovered in the first 12-h urine and was distributed in the following metabolites (relative ratios): unchanged NG,NG-dimethyl-L-arginine (35.2%), gamma-(N,N-dimethylguanidino)butyric acid (18.4%), alpha-keto-delta-(N,N-dimethylguanidino)valeric acid (16.4%), and N alpha-acetyl-NG,NG-dimethyl-L-arginine (8.5%). The radioactivity retained in the tissues was found mainly in citrulline and was further distributed in ornithine, arginine, and glutamic acid and even in protein-bound arginine. In the case of NG,N'G-dimethyl-L-[1,2,3,4,5-14C]arginine-injected rats, about 75% of the radioactivity was excreted in the first 12-h urine and was recovered in the following metabolites (relative ratios): N alpha-acetyl-NG,N'G-dimethyl-L-arginine (48.4%), unchanged NG,N'G-dimethyl-L-arginine (23.7%), alpha-keto-delta-(N,N'-dimethylguanidino)valeric acid (20.2%), and gamma-(N,N'-dimethylguanidino)butyric acid (9.6%). In the tissues, most of the radioactivity was associated with unchanged NG,N'G-dimethyl-L-arginine. These findings show that both dimethylarginines are metabolized by a pathway forming the corresponding alpha-ketoacid analogs and the oxidatively decarboxylated products of the alpha-ketoacids in addition to the N alpha-acetyl conjugates identified previously (K. Sasaoka, T. Ogawa, and M. Kimoto (1982) Arch. Biochem. Biophys. 219, 454-458), and NG,NG-dimethyl-L-arginine is catabolized by an additional pathway leading to the formation of citrulline and its metabolically related amino acids. By considering their catabolism, an attempt to use urinary dimethylarginines as an index of in vivo breakdown of tissue proteins is invalid at least in rats.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3101600     DOI: 10.1016/0003-9861(87)90060-9

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  36 in total

1.  Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine.

Authors:  Xinli Hu; Dorothee Atzler; Xin Xu; Ping Zhang; Haipeng Guo; Zhongbing Lu; John Fassett; Edzard Schwedhelm; Rainer H Böger; Robert J Bache; Yingjie Chen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-04-14       Impact factor: 8.311

2.  Dimethylguanidino valeric acid is a marker of liver fat and predicts diabetes.

Authors:  John F O'Sullivan; Jordan E Morningstar; Qiong Yang; Baohui Zheng; Yan Gao; Sarah Jeanfavre; Justin Scott; Celine Fernandez; Hui Zheng; Sean O'Connor; Paul Cohen; Ramachandran S Vasan; Michelle T Long; James G Wilson; Olle Melander; Thomas J Wang; Caroline Fox; Randall T Peterson; Clary B Clish; Kathleen E Corey; Robert E Gerszten
Journal:  J Clin Invest       Date:  2017-10-30       Impact factor: 14.808

Review 3.  Nitric oxide synthases in mammals.

Authors:  R G Knowles; S Moncada
Journal:  Biochem J       Date:  1994-03-01       Impact factor: 3.857

Review 4.  Asymmetric dimethylarginine and reactive oxygen species: unwelcome twin visitors to the cardiovascular and kidney disease tables.

Authors:  Christopher S Wilcox
Journal:  Hypertension       Date:  2012-01-03       Impact factor: 10.190

5.  Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients.

Authors:  Xun Bao; Jianmei Wu; Seongho Kim; Patricia LoRusso; Jing Li
Journal:  J Clin Pharmacol       Date:  2018-07-27       Impact factor: 3.126

6.  Human alanine-glyoxylate aminotransferase 2 lowers asymmetric dimethylarginine and protects from inhibition of nitric oxide production.

Authors:  Roman N Rodionov; Daryl J Murry; Sarah F Vaulman; Jeff W Stevens; Steven R Lentz
Journal:  J Biol Chem       Date:  2009-12-14       Impact factor: 5.157

7.  AGXT2 and DDAH-1 genetic variants are highly correlated with serum ADMA and SDMA levels and with incidence of coronary artery disease in Egyptians.

Authors:  Mina Amir; Sally I Hassanein; Mohamed F Abdel Rahman; Mohamed Z Gad
Journal:  Mol Biol Rep       Date:  2018-10-03       Impact factor: 2.316

Review 8.  Asymmetric dimethylarginine as a mediator of vascular dysfunction in cirrhosis.

Authors:  Paloma Lluch; Gloria Segarra; Pascual Medina
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

9.  N(G)-Methylarginines: Biosynthesis, biochemical function and metabolism.

Authors:  W K Paik; S Kim
Journal:  Amino Acids       Date:  1993-10       Impact factor: 3.520

10.  Blood content of asymmetric dimethylarginine: new insights into its dysregulation in renal disease.

Authors:  Scott S Billecke; Louis G D'Alecy; Raylene Platel; Steven E Whitesall; Kenneth A Jamerson; Rachel L Perlman; Crystal A Gadegbeku
Journal:  Nephrol Dial Transplant       Date:  2008-09-15       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.